January 2026 in “BULLETIN OF STOMATOLOGY AND MAXILLOFACIAL SURGERY” Both treatments help hair regrowth, but Botulinum Toxin-A has fewer side effects.
January 2026 in “Journal of Dermatology Research and Therapy” Combination therapy effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.
A rare skin reaction occurred when a man took paracetamol, causing a new rash in an area already affected by hair loss.
January 2026 in “Journal of the Egyptian Womenʼs Dermatologic Society” High levels of HSP70 and IL-15 are linked to more severe alopecia areata.
January 2026 in “International Journal of All Research Education & Scientific Methods” Alopecia is caused by various factors, and new treatments like gene editing and regenerative medicine offer hope for personalized hair regrowth solutions.
January 2026 in “International Journal of Research and Innovation in Applied Science” Ayurvedic treatment may help manage alopecia areata.
December 2025 in “Cosmetics” New treatments for alopecia show promise in restoring hair growth by targeting immune and hormonal factors.
December 2025 in “Reports of Vinnytsia National Medical University” Alopecia areata affects life quality differently based on its severity.
December 2025 in “Clinical Case Reports” Exosome therapy helped regrow and repigment beard hair in a man with alopecia.
November 2025 in “International Journal of Research in Medical Sciences” Diffuse alopecia in females is often linked to certain medications, diseases, and low hemoglobin, while female pattern hair loss is linked to age, duration, and family history.
November 2025 in “The Bioscan.” Pix Liquida may help treat alopecia areata.
November 2025 in “Journal of Investigative Dermatology” Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.
November 2025 in “F1000Research” Certain fungi may contribute to hair loss in cynomolgus macaques.
November 2025 in “Bioscientia Medicina Journal of Biomedicine and Translational Research” A combined treatment with microneedling and vitamin D3 led to complete hair regrowth in a woman with stubborn patch alopecia areata.
November 2025 in “SHILAP Revista de lepidopterología” Animal and mathematical models help understand and develop treatments for alopecia areata.
October 2025 in “Pakistan Journal of Health Sciences” Low serum ferritin is linked to hair loss in women.
October 2025 in “Dermatology Practical & Conceptual” Psoriasis patients are more likely to develop alopecia areata due to complex autoimmune interactions.
October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
October 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Hair loss negatively impacts quality of life, and psychological support can help.
October 2025 in “Indian Dermatology Online Journal” 2.5 mg/ml of triamcinolone acetonide is more effective for treating alopecia areata.
Baricitinib effectively regrows hair in severe alopecia areata cases.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
September 2025 in “Cyprus Journal of Medical Sciences” Alopecia areata significantly increases anxiety, depression, and reduces quality of life.
September 2025 in “Journal of Dhaka Medical College” Lower vitamin D levels are linked to more severe alopecia areata.
September 2025 in “JAAD Case Reports” Hair extensions can worsen scalp conditions and should be avoided in those with alopecia.
September 2025 in “Asian journal of pediatric dermatology.” Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
August 2025 in “JURNAL PEMBELAJARAN DAN BIOLOGI NUKLEUS” Alopecia in bats is more common in urban areas due to habitat conditions.
Dupilumab may cause hair loss, so patients should be monitored.
July 2025 in “American Journal of Clinical Dermatology” Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
July 2025 in “International Journal of Pharmaceutical Sciences Review and Research” Individualized treatment and psychological support improved the patient's quality of life and appearance despite medication side effects.